文献速递肾癌与肾肿瘤

转移性肾细胞癌对舒尼替尼快速进展:下一步该怎么办?

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
PubMed 文献 · Eur Urol Oncol · 2019-07-20

研究回顾性收集19个欧洲肿瘤中心2005年3月至2011年3月间150例一线舒尼替尼快速进展的转移性肾细胞癌患者资料,评估后续使用另一种酪氨酸激酶抑制剂(TKI)或哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂的获益。结果显示二线TKI与mTOR抑制剂的二线无进展生存无显著差异(2.0 vs 0.9个月;p=0.536),作者认为获益甚微,建议避免TKI再挑战,或可优先考虑免疫检查点抑制剂等替代策略。

要点

  • 10%至26%的转移性肾细胞癌患者在接受舒尼替尼治疗时出现快速进展。
  • 二线TKI与mTOR抑制剂的二线无进展生存无显著差异(2.0 vs 0.9个月;p=0.536)。
  • 作者认为对一线舒尼替尼原发耐药者后续TKI或mTOR抑制剂获益甚微。

核心结论

  • 在观察时间段内,对一线舒尼替尼原发耐药的转移性肾细胞癌患者,后续使用TKI或mTOR抑制剂获益甚微。
  • 作者建议避免TKI再挑战,或可优先考虑免疫检查点抑制剂等替代策略。

研究设计与样本

  • 回顾性研究,通过问卷收集19个欧洲肿瘤中心2005年3月至2011年3月的数据。
  • 共纳入150例一线舒尼替尼快速进展的转移性肾细胞癌患者,其中两个周期内进展93例、四个周期内进展57例。
  • 中位年龄59岁;86%行肾切除术;组织学亚型为透明细胞癌77.8%、乳头状癌14%、肉瘤样特征18%。
  • 根据纪念斯隆-凯特琳癌症中心分类,良好风险11%、中等风险68%、poor风险21%;根据法国分类,良好风险7%、中等风险63%、poor风险29%。

主要发现

  • 自一线治疗开始的中位总生存为7.4个月。
  • 86例(57%)患者接受二线治疗:44例mTOR抑制剂(23例依维莫司、21例替西罗莫司)、39例单用或联合TKI、3例化疗。
  • 二线无进展生存TKI与mTOR抑制剂无显著差异(2.0 vs 0.9个月;p=0.536)。
  • 自二线治疗开始的中位总生存mTOR抑制剂为5.0个月,TKI为6.6个月(p=0.15)。

临床怎么用

  • 作者认为对一线舒尼替尼原发耐药的转移性肾细胞癌患者,后续TKI或mTOR抑制剂获益甚微,建议避免TKI再挑战。
  • 作者提出在此类患者中或可优先考虑免疫检查点抑制剂等替代策略。

局限性

  • 数据为回顾性收集。
  • 数据通过问卷收集。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: From 10% to 26% of patients with metastatic renal cell carcinoma (mRCC) experience rapidly progressive disease (PD) on treatment with sunitinib. OBJECTIVE: To investigate the benefit of subsequent treatment with another tyrosine kinase inhibitor (TKI) or a mammalian target of rapamycin (mTOR) inhibitor in such primary refractory patients. DESIGN, SETTING, AND PARTICIPANTS: A total of 150 mRCC patients with rapidly PD on first-line sunitinib (within two cycles, n=93, or four cycles, n=57) were identified: median age 59yr; nephrectomy 86%; histological subtypes: clear cell (77.8%), papillary (14%), and sarcomatoid features (18%); according to the Memorial Sloan-Kettering Cancer Center and French classifications: good risk (11% and 7%, respectively), intermediate (68% and 63%, respectively), and poor (21% and 29%, respectively). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Data were retrospectively collected by a questionnaire from 19 European oncology centers between March 2005 and March 2011. Progression-free survival (PFS) and overall survival (OS) were calculated (Kaplan-Meier method). RESULTS AND LIMITATIONS: Median OS from the start of first-line treatment was 7.4mo. Second-line treatment was administered to 86 (57%) patients (44 mTOR inhibitors: 23 everolimus and 21 temsirolimus; 39 TKIs alone or in combination; three chemotherapy). Second-line PFS was not significantly different between TKIs and mTOR inhibitors (2.0 vs 0.9mo; p=0.536). Median OS from the start of second-line treatment was 5.0mo for mTOR inhibitors and 6.6mo for TKIs (p=0.15). CONCLUSIONS: Treatment with further TKIs or mTOR inhibitors for mRCC patients primarily refractory to first-line sunitinib in the observed time period achieved very minimal benefit, suggesting avoiding TKI rechallenge and possibly preferring alternative strategies, such as immune checkpoint inhibitors, after PD to a treatment line including a TKI in this setting. PATIENT SUMMARY: The present work collected data about 150 patients affected by metastatic renal cell carcinoma, who received one of the current standard of care as first-line treatment, namely, the antiangiogenic drug sunitinib, and experienced rapid worsening of the disease. We investigated and described the subsequent outcome of such patients treated with two different types of drug, administered as second-line therapy, to better understand the best strategy to adopt for patients who got no benefit from sunitinib and to describe the current therapeutic approach in such cases.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bersanelli M, Iacovelli R, Buti S, et al. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? Eur Urol Oncol. 2019. PMID: 31331862. doi:10.1016/j.euo.2019.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。